CPT-11 and L-OHP combination versus alternated combination of LV5FU2+CPT-11/LV5FU2+L-OHP in 5-FU resistant advanced colorectal cancer (CRC): Preliminary results

被引：1
|
作者：
Becouam, Y
Mousseau, M
Gamelin, E
Coudert, B
Marceau-Suissa, J
Bekradda, M
机构：
[1] Inst Bergonie Bordeaux, Bordeaux, France
[2] CHU Grenoble, F-38043 Grenoble, France
[3] Ctr Paul Papin, Angers, France
[4] Ctr F Leclerc, Dijon, France
[5] Rhone Poulenc Rorer, Montrouge, France
[6] C&AC Kremlin Bicetre, Le Kremlin Bicetre, France
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)80652-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
219
引用
收藏
页码：S71 / S71
页数：1
相关论文
共 50 条
  • [21] A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
    Oliver F Bathe
    Scott Ernst
    Francis R Sutherland
    Elijah Dixon
    Charles Butts
    David Bigam
    David Holland
    Geoffrey A Porter
    Jennifer Koppel
    Scot Dowden
    BMC Cancer, 9
  • [22] 5-FLUOROURACIL (5-FU) COMBINED WITH LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED 5-FU RESISTANT COLORECTAL-CANCER
    VANGROENINGEN, CJ
    PETERS, GJ
    PINEDO, HM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 202 - 202
  • [23] L-OHP联合5-FU/LV二线治疗晚期肠癌26例分析
    王晓丽
    中国误诊学杂志, 2008, (12) : 2969 - 2969
  • [24] A phase I study of concomitant CPT-11 (C) and 5FU (F) combination: Preliminary results
    Rixe, O
    Benhammouda, A
    Farabos, C
    Borel, C
    Petit, T
    Auclerc, G
    Coeffic, D
    Bastian, G
    Grossin, F
    Paraiso, D
    Grapin, JP
    Nizri, D
    Weil, M
    Bismuth, H
    Mahjoubi, M
    Khayat, D
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 955 - 955
  • [25] Final results of first line treatment with 5-fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (L-OHP) in advanced colorectal cancer (ACC): A multicenter phase II study.
    Souglakos, J
    Kouroussis, C
    Ziras, N
    Malamos, N
    Potamianou, A
    Mavroudis, D
    Kakolyris, S
    Androulakis, N
    Vardakis, N
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2000, 11 : 49 - 49
  • [26] A phase II study of alternating cycles of CPT-11 and high-dose 48 hour infusion 5-FU in combination with leucovorin (HD-5-FU/LV) in no selective patients with metastatic colorectal cancer (MCRC)
    Rosati, G
    Bilancia, D
    De Santis, S
    Dinota, A
    Rossi, A
    Manzione, L
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S81 - S81
  • [27] Phase I study of CPT-11 and bolus 5-FU/l-leucovorin in patients with metastatic colorectal cancer
    Fujishima H.
    Kikuchi I.
    Miyanaga O.
    Ueda A.
    Baba E.
    Mitsugi K.
    Harada M.
    Nakano S.
    International Journal of Clinical Oncology, 2004, 9 (2) : 92 - 97
  • [28] Phase I/II study of CPT-II in combination with LV5FU2 (De Gramont-Regimen) every 2 weeks for the treatment of colorectal cancer (CRC) after 5-FU failure
    Seitz, JF
    Ducreux, M
    Ychou, M
    Bonnay, M
    Rougier, P
    Mignard, D
    Armand, JP
    ANNALS OF ONCOLOGY, 1998, 9 : 68 - 68
  • [29] Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
    Van Cutsem, E
    Cunningham, D
    Huinink, WWT
    Punt, CJA
    Alexopoulos, CG
    Dirix, L
    Symann, M
    Blijham, GH
    Cholet, P
    Fillet, G
    Van Groeningen, C
    Vannetzel, JM
    Levi, F
    Panagos, G
    Unger, C
    Wils, J
    Cote, C
    Blanc, C
    Hérait, P
    Bleiberg, H
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (01) : 54 - 59
  • [30] Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU):: A phase II study
    Antón, A
    Aranda, E
    Carrato, A
    Marcuello, E
    Massutti, B
    Cervantes, A
    Abad, A
    Sastre, J
    Fenández-Martos, C
    Gallén, M
    Díaz-Rubio, E
    Huarte, L
    Balcells, M
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (08): : 639 - 643
12345